Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company, has announced its participation in the 2026 Leerink Partners Global Healthcare Conference. Scheduled for March 11, 2026, at 2:20 p.m. ET, the presentation will provide an opportunity for the company's management to discuss its innovative therapies targeting neuroscience, inflammation, and immunology (NI&I) conditions. An audio webcast will be available for investors and stakeholders on the company’s website, along with a replay following the event.

Contineum Therapeutics specializes in developing novel oral small molecule therapies aimed at addressing significant unmet medical needs within the NI&I space. The company is advancing a promising pipeline of internally developed programs, featuring multiple candidates currently undergoing clinical trials. Key among these is PIPE-791, an LPA1 receptor antagonist being tested for applications in idiopathic pulmonary fibrosis and chronic pain. Another notable candidate is PIPE-307, a selective M1 receptor inhibitor advancing in clinical trials for relapsing-remitting multiple sclerosis and major depressive disorder.

With an ambitious strategy centered around innovative therapies, Contineum aims to make a significant impact on the treatment landscape within its focus areas. The company’s commitment to tackling challenging diseases is underscored by its robust clinical development efforts.

Investors and interested parties can find additional information at the company’s website, www.contineum-tx.com. For further inquiries, Steve Kunszabo, Senior Director of Investor Relations & Corporate Communications, is available for contact.

Overall, Contineum Therapeutics is positioning itself as a key player in the biopharmaceutical industry, with a focus on developing breakthrough therapies for challenging neurological and inflammatory conditions.

Contineum Therapeutics, Inc. (NASDAQ: CTNM) is poised for potential investor interest as it prepares for its presentation at the 2026 Leerink Partners Global Healthcare Conference. As a clinical-stage biopharmaceutical company focusing on neuroscience, inflammation, and immunology, Contineum occupies a unique space in the market, particularly with its promising pipeline of drug candidates targeting significant unmet medical needs.

The presentation scheduled for March 11th is crucial as it will provide the management team an opportunity to articulate their vision and progress, focusing on clinical trials for their lead candidates, PIPE-791 and PIPE-307. PIPE-791, an LPA1 receptor antagonist, shows promise in treating idiopathic pulmonary fibrosis and chronic pain, representing potential avenues in the growing respiratory and pain management markets. Similarly, PIPE-307’s targeted approach for relapsing-remitting multiple sclerosis and major depressive disorder aligns with increasing demand for effective therapies in neurodegenerative and mood disorders.

From an investment perspective, the forthcoming presentation could serve as a catalyst for stock performance. Analysts and investors will be keen to assess trial data, strategic collaborations, potential partnerships, and the regulatory pathway ahead. Given the current dynamics in the biopharma sector, favorable clinical trial results can significantly enhance the market outlook for CTNM.

However, it’s important for investors to weigh the risks associated with clinical-stage biopharmaceutical companies, including market volatility and regulatory hurdles. Diversification within the biotech portfolio is advisable. Overall, the upcoming conference could ignite investor interest, but careful tracking of pipeline developments and market conditions will be essential to capitalize on potential growth opportunities with Contineum Therapeutics.